- Home
- HMR vs CHRS Comparison
HMR vs CHRS Comparison
Compare HMR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMR
- CHRS
- Stock Information
- Founded
- HMR 1984
- CHRS 2010
- Country
- HMR Greece
- CHRS United States
- Employees
- HMR N/A
- CHRS N/A
- Industry
- HMR Marine Transportation
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HMR Consumer Discretionary
- CHRS Health Care
- Exchange
- HMR Nasdaq
- CHRS Nasdaq
- Market Cap
- HMR 99.5M
- CHRS 102.0M
- IPO Year
- HMR N/A
- CHRS 2014
- Fundamental
- Price
- HMR $1.53
- CHRS $0.87
- Analyst Decision
- HMR Strong Buy
- CHRS Buy
- Analyst Count
- HMR 2
- CHRS 3
- Target Price
- HMR $6.00
- CHRS $4.68
- AVG Volume (30 Days)
- HMR 137.0K
- CHRS 1.4M
- Earning Date
- HMR 06-10-2025
- CHRS 08-11-2025
- Dividend Yield
- HMR N/A
- CHRS N/A
- EPS Growth
- HMR N/A
- CHRS N/A
- EPS
- HMR N/A
- CHRS N/A
- Revenue
- HMR $26,159,037.00
- CHRS $272,251,000.00
- Revenue This Year
- HMR $6.54
- CHRS N/A
- Revenue Next Year
- HMR $41.26
- CHRS $142.61
- P/E Ratio
- HMR N/A
- CHRS $2.06
- Revenue Growth
- HMR N/A
- CHRS 19.87
- 52 Week Low
- HMR $1.45
- CHRS $0.66
- 52 Week High
- HMR $10.04
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- HMR N/A
- CHRS 47.28
- Support Level
- HMR N/A
- CHRS $0.88
- Resistance Level
- HMR N/A
- CHRS $1.15
- Average True Range (ATR)
- HMR 0.00
- CHRS 0.08
- MACD
- HMR 0.00
- CHRS -0.00
- Stochastic Oscillator
- HMR 0.00
- CHRS 18.26
About HMR Heidmar Maritime Holdings Corp. Common Stock
Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.